Oxford Genome Sciences (UK) Ltd.
This article was originally published in Start Up
Executive Summary
The founders of Oxford Genome Sciences believe in the promise of personalized medicine, and are pursuing it directly-with assets and insights they say will enable the start-up to quickly achieve commercial goals. The company is intent on leveraging its OGAP database, which contains sequences of proteins from nearly a million human tissue samples, as well as human tumor cell lines and cerebrospinal fluid.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.